Scientific Advisor, Advent Life Sciences Fraser is a neuropharmacologist with almost 30 years of drug discovery and early development experience across a range of therapeutic areas, including neurodegeneration, psychiatry, inflammation, gastrointestinal and dermatology. He has a wide C-suite experience in multiple biotech startups and held leadership roles at Shire, AstraZeneca,
Investment Director, Life Sciences, Bpifrance Investissements Since 2014 at Bpifrance Investissements, Benoit has been involved in a dozen investment deals and current board member positions include Alentis, Dynacure, Igyxos, Meiogenix and BrainEver. Prior to this, he gained experience in various biotech roles, co-discovered a vaccine candidate, and developed an antibody
Partner, AdBio Partners Clément Bertholet spent the first part of this carreer between life science and corporate finance. He graduated from Ecole Normale Supérieure (ENS Paris Saclay) with a major in Biology and Health and several experiences in Institut Curie and Cancer Research UK, before joining the Corps des Mines, a
Holger brings over 20 years of experience in Pharma, Biotech and Healthtech spanning multiple therapeutic areas and major elements of the value chain. He worked many years with Boehringer Ingelheim (BI) in different roles including Corporate VP Strategy and General Manager in European countries. Prior to joining BI, Holger was a